[Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia].
Zhonghua Yan Ke Za Zhi
; 55(10): 791-795, 2019 Oct 11.
Article
em Zh
| MEDLINE
| ID: mdl-31607068
ABSTRACT
Pathological myopia refers to high myopia with fundus pathological changes. Choroidal neovascularization is one of its serious complications, and also the main cause of visual loss. Currently, the first-line treatment is anti-VEGF treatment, with good efficacy, high safety, good prognosis, and other advantages of vision. Commonly used anti-VEGF drugs include bevacizumab, ranibizumab, aflibercept, and conbercept. The main treatment strategies include 1+pro re nata and 3+pro re nata, and the standard of REPAIR test is often used to evaluate the re-injection. This article reviews the advantages of anti-VEGF therapy, drug selection, treatment strategy, and re-injection criteria. (Chin J Ophthalmol, 2019, 55791-795).
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neovascularização de Coroide
/
Inibidores da Angiogênese
/
Miopia Degenerativa
/
Bevacizumab
/
Ranibizumab
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
Zh
Revista:
Zhonghua Yan Ke Za Zhi
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
China